Tonix Pharmaceuticals Hld

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CHATHAM, N.J., Feb. 09, 2021 (GLOBE NEWSWIRE) -- TONIX PHARMACEUTICALS HOLDINGS CORP. (NASDAQ: TNXP) (“Tonix” or the “Company”), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced registered direct offering, priced at-the-market, with gross proceeds of approximately $70.0 million before deducting fees and other estimated offering expenses. The Company sold 58,333,334 shares of common stock at $1.20 per share.

Tonix Pharmaceuticals Holdings Corp. Closes $70M Common Stock Offering Priced At-The-Market Under Nasdaq Rules

The biotech wants to help doctors measure T-cell immunity to the novel coronavirus.

Why Tonix Pharmaceuticals Stock Surged Today

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) has entered into a securities purchase agreement with institutional investors to purchase 58.3 million shares at $1.20 per share, raising gross proceeds of approximately $70 million. The offering is expected to close by February 9.

Tonix Pharmaceuticals $70M; Plans To Develop COVID-19 Skin Test

CHATHAM, N.J., Feb. 08, 2021 (GLOBE NEWSWIRE) -- TONIX PHARMACEUTICALS HOLDINGS CORP. (NASDAQ: TNXP) (“Tonix” or the “Company”), a clinical-stage biopharmaceutical company, today announced it has entered into a securities purchase agreement with institutional investors for the purchase and sale of 58,333,334 shares of common stock, par value $0.001 per share at an offering price of $1.20 per share, pursuant to a registered direct offering, priced at-the-market under Nasdaq rules. The gross proceeds of the offering will be approximately $70 million before deducting fees and other estimated offering expenses. The closing of the registered direct offering is expected to take place on or about February 9, 2021, subject to the satisfaction of customary closing conditions.

Tonix Pharmaceuticals Holdings Corp. Prices $70M Common Stock Offering Priced At-The-Market Under Nasdaq Rules

Annovis Bio

Annovis Bio (NYSE: ANVS) shares were trading higher Thursday after the company announced the European Patent Office granted the company's patent for a method of treating acute nerve and brain injuries by administering ANVS405 after an injury. Annovis Bio is a clinical stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neuro degenerative diseases.

Why Annovis Bio, Tonix Pharma Are Trading Higher Today

TNXP stock is on the move today as investors speculate over potential patent approval and Tonix's drug candidate for Alzheimer's. The post TNXP Stock: Why Tonix Pharmaceuticals Shares Are on the Move Today appeared first on InvestorPlace.

TNXP Stock: Why Tonix Pharmaceuticals Shares Are on the Move Today

The stock price of Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) is trading at over 30% pre-market today as of 5:06 AM ET. This is why it happened.

TNXP Stock Price Increases Over 30% Pre-Market: Why It Happened

Tonix Pharmaceuticals was one of the sponsors for the Benzinga Global Small Cap Conference that took place on December 8-9, 2020. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only.

Tonix Pharmaceuticals CEO Believes That Additional COVID-19 Vaccine Research Is Still Needed

GMP Production of TNX-1500 is Expected to be Available in the Third Quarter of 2021

Tonix Pharmaceuticals Announces Publication of Patent Application for TNX-1500 (Monoclonal Antibody Anti-CD40-Ligand) in Development for Preventing and Treating Organ Transplant Rejection and Treating Autoimmune Conditions

CHATHAM, N.J., Jan. 13, 2021 (GLOBE NEWSWIRE) -- TONIX PHARMACEUTICALS HOLDINGS CORP. (NASDAQ: TNXP) (“Tonix” or the “Company”), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced registered direct offering, priced at-the-market, with gross proceeds of $40.0 million before deducting fees and other estimated offering expenses.

Tonix Pharmaceuticals Holdings Corp. Closes $40M Common Stock Offering Priced At-the-Market Under Nasdaq Rules

CHATHAM, N.J., Jan. 11, 2021 (GLOBE NEWSWIRE) -- TONIX PHARMACEUTICALS HOLDINGS CORP. (NASDAQ: TNXP) (“Tonix” or the “Company”), a clinical-stage biopharmaceutical company, today announced it has entered into a securities purchase agreement with institutional investors for the purchase and sale of 50,000,000 shares of common stock, par value $0.001 per share at an offering price of $0.80 per share, pursuant to a registered direct offering, priced at-the-market under Nasdaq rules. The gross proceeds of the offering will be $40,000,000 before deducting fees and other estimated offering expenses. The closing of the registered direct offering is expected to take place on or about January 13, 2021, subject to the satisfaction of customary closing conditions.

Tonix Pharmaceuticals Holdings Corp. Prices $40M Common Stock Offering Priced at-the-Market Under Nasdaq Rules

BIOLASE

Jaguar Health

Senseonics Holdings

This article is going to explain what penny stocks are and discuss four penny stocks under $1 to watch as small-cap stocks continue a hot streak this winter. First thing's first, what are penny stocks?

4 Hot Penny Stocks Trading Under $1 That Need To Be On Your Watchlist

Hamilton, MT Facility Is Planned to Manufacture Vaccines at Commercial Scale, Including Vaccines Under Development for COVID-19

Tonix Pharmaceuticals Plans Commercial Scale Vaccine Manufacturing Facility

University of Geneva Technology Covers Broad Applications for Cardiometabolic Syndromes University of Geneva Technology Covers Broad Applications for Cardiometabolic Syndromes

Tonix Pharmaceuticals Acquires Exclusive License to University of Geneva Technology for Oxytocin-Based Treatments for Treating Insulin Resistance, Diabetes and Obesity, Expanding Proprietary Uses for TNX-1900 (Intranasal Potentiated Oxytocin)

Tonix Pharmaceuticals (TNXP) news for Monday includes results from a recent Phase 3 clinical trial boosting TNXP stock higher. The post Tonix Pharmaceuticals News: TNXP Stock Soars on Fibromyalgia Drug Results appeared first on InvestorPlace.

Tonix Pharmaceuticals News: TNXP Stock Soars on Fibromyalgia Drug Results

Anti-SARS-CoV-2 Neutralizing Antibodies Elicited in All Eight TNX-1800 Vaccinated Animals

Tonix Pharmaceuticals Reports Positive Immune Response Results from COVID-19 Vaccine Candidate TNX-1800, Following Vaccination of Non-Human Primates

Increasing Placebo Responses in PTSD Drug Trials Raise Questions About Current Methods of Measuring or Analyzing PTSD Symptom Change Over Time

Tonix Pharmaceuticals Outlines New Statistical Method to Analyze Future PTSD Studies at the 3rd Annual Neuropsychiatric Drug Development Summit

Can-Fite BioPharma Ltd.

Five Prime Therapeutics

GT Biopharma Inc

InflaRx

vTv Therapeutics

Vaxart

With the pandemic drawing much attention toward biotech stocks, there are some interesting ideas among in the small-cap field, but only if you understand the severe risks involved. The post 7 Biotech Penny Stocks Worth a Gamble appeared first on InvestorPlace.

7 Biotech Penny Stocks Worth a Gamble

CHATHAM, N.J., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, has been invited to present at three upcoming virtual investor conferences in November.

Tonix Pharmaceuticals to Participate in Upcoming November Conferences

CHATHAM, N.J., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will be an invited speaker at the 3rd Annual Neuropsychiatric Drug Development Summit being held virtually November 10-12, 2020.

Tonix Pharmaceuticals to Present at 3rd Annual Neuropsychiatric Drug Development Summit

Data from Animal Studies of COVID-19 Vaccine Candidate, TNX-1800, Expected in Fourth Quarter 2020

Tonix Pharmaceuticals Reports Third Quarter 2020 Financial Results and Operational Highlights

Study May Lead to Biomarkers for Tailoring COVID-19 Vaccines and Therapeutics

Tonix Pharmaceuticals Enrolls First Participant in the PRECISION Study, an Observational Study to Facilitate Development of Precision Medicine Techniques for COVID-19 Vaccines and Therapeutics

CHATHAM, N.J., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will deliver a Company presentation and host one-on-one meetings during the 2020 BIO Investor Forum Digital, being held virtually October 13-15, 2020. The Company’s presentation will be available on demand to registered participants through the conference website.

Tonix Pharmaceuticals to Participate in BIO Investor Forum Digital

Topline Results of Full Study Expected Fourth Quarter 2020

Tonix Pharmaceuticals Announces Plan to Complete the Phase 3 RELIEF Study of TNX-102 SL for Management of Fibromyalgia with Currently Enrolled Participants Based on Results of Interim Analysis

Facility Addresses the Shortage of Vaccine Production Capacity in the U.S.

News for Tonix Pharmaceuticals Hld Stock (TNXP)